http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114231497-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2469-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-165 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-581 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-577 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56983 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-577 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-569 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14 |
| filingDate | 2022-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-114231497-B |
| titleOfInvention | Monoclonal antibody hybridoma cell line expressing SARS-CoV-2S 1 protein and neutralizing active antibody |
| abstract | The invention belongs to the field of cell engineering and immunology, and particularly relates to a hybridoma cell line for expressing a monoclonal antibody of a novel coronavirus S1 protein and a neutralizing active antibody. The invention obtains a hybridoma cell line which can efficiently and stably secrete and express the monoclonal antibody of the new coronavirus S1 protein and the monoclonal antibody of the new coronavirus S1 protein secreted by the hybridoma cell line by screening; the recombinant hybridoma cell line is cultured by using a common cell culture dish, the yield can reach 10mg/L, and the purity can reach more than 90 percent; the monoclonal antibody of the invention has high neutralizing activity, can inhibit over 50 percent of new corona pseudovirus activity when the concentration of the monoclonal antibody is 0.00103 mug/mL, and is the best neutralizing activity of the new corona pseudovirus reported at present. The hybridoma cell line or the monoclonal antibody provided by the invention has important application value in serological detection of the new coronavirus, preparation of a reagent or a medicament for infection of the new coronavirus and preparation of a reagent for detecting an antigen or an antibody of the new coronavirus. |
| priorityDate | 2022-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 529.